Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.
暂无分享,去创建一个
F. Saad | A. Briganti | S. Shariat | P. Karakiewicz | A. Kapoor | L. Kluth | A. Becker | O. de Cobelli | Z. Tian | D. Tilki | C. Terrone | A. Panunzio | F. Barletta | A. Antonelli | Nancy Nimer | S. Tappero | M. Piccinelli | F. Chun | Cristina Cano Garcia | R. Incesu | C. Cano Garcia | F. Saad | Anil Kapoor | C. Terrone | S. Shariat | D. Tilki | A. Antonelli | O. De Cobelli | Andreas Becker | F. Chun
[1] F. Saad,et al. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity , 2022, International Urology and Nephrology.
[2] M. Graefen,et al. Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data , 2021, The Prostate.
[3] F. Saad,et al. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups , 2021, International journal of urology : official journal of the Japanese Urological Association.
[4] R. Motzer,et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. , 2020, Cancer.
[5] R. Motzer,et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Saad,et al. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities , 2020, Cancer Causes and Control.
[7] R. Motzer,et al. Towards individualized therapy for metastatic renal cell carcinoma , 2019, Nature Reviews Clinical Oncology.
[8] R. Motzer,et al. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. , 2019, European urology.
[9] F. Saad,et al. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. , 2019, European urology focus.
[10] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[11] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[12] J. Gore,et al. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. , 2015, Urology.
[13] K. Schwartz,et al. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. , 2014, Clinical genitourinary cancer.
[14] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.